GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (FRA:JC4) » Definitions » EV-to-FCF

Universal Ibogaine (FRA:JC4) EV-to-FCF : -8.23 (As of Dec. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Universal Ibogaine EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Universal Ibogaine's Enterprise Value is €4.63 Mil. Universal Ibogaine's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2024 was €-0.56 Mil. Therefore, Universal Ibogaine's EV-to-FCF for today is -8.23.

The historical rank and industry rank for Universal Ibogaine's EV-to-FCF or its related term are showing as below:

FRA:JC4' s EV-to-FCF Range Over the Past 10 Years
Min: -41.14   Med: -4.05   Max: -1.08
Current: -8.43

During the past 7 years, the highest EV-to-FCF of Universal Ibogaine was -1.08. The lowest was -41.14. And the median was -4.05.

FRA:JC4's EV-to-FCF is ranked worse than
100% of 386 companies
in the Biotechnology industry
Industry Median: 8.605 vs FRA:JC4: -8.43

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-11), Universal Ibogaine's stock price is €0.0075. Universal Ibogaine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2024 was €-0.004. Therefore, Universal Ibogaine's PE Ratio (TTM) for today is At Loss.


Universal Ibogaine EV-to-FCF Historical Data

The historical data trend for Universal Ibogaine's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine EV-to-FCF Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23
EV-to-FCF
Get a 7-Day Free Trial -23.13 -13.81 -9.08 -1.95 -3.66

Universal Ibogaine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.64 -3.66 -3.20 -8.41 -8.11

Competitive Comparison of Universal Ibogaine's EV-to-FCF

For the Biotechnology subindustry, Universal Ibogaine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Ibogaine's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's EV-to-FCF falls into.



Universal Ibogaine EV-to-FCF Calculation

Universal Ibogaine's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4.631/-0.563
=-8.23

Universal Ibogaine's current Enterprise Value is €4.63 Mil.
Universal Ibogaine's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Universal Ibogaine  (FRA:JC4) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Universal Ibogaine's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0075/-0.004
=At Loss

Universal Ibogaine's share price for today is €0.0075.
Universal Ibogaine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.004.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Universal Ibogaine EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Ibogaine Business Description

Traded in Other Exchanges
Address
815 8th Avenue South West, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

Universal Ibogaine Headlines

No Headlines